GENOMICS AND RATIONALLY TARGETED THERAPIES IN ACUTE LYMPHOBLASTIC LEUKAEMIA
Professor Deborah White
Theme Leader Precision Cancer Medicine &
Group Leader Acute Lymphoblastic Leukaemia Group
South Australian Health and Medical Research Institute (SAHMRI)
Adelaide, South Australia
RESEARCHER PROFILE
Filmed in Adelaide, South Australia | February 2025
Professor White is the Precision Medicine Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI) in Adelaide. She is a NHMRC RD Wright Biomedical Research Fellow, a Beat Cancer Principal Research Fellow and Senior Principal Research Fellow with SAHMRI. She is a Professor in Health and Medical Sciences at the University of Adelaide and Health Sciences at University of South Australia.
Prof White’s research focus is genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia (ALL) and Chronic Myeloid Leukaemia (CML) and she holds peer reviewed grants from: The William Lawrence and Blanche Hughes Foundation and the Leukemia & Lymphoma Society (USA), the NHMRC, the Leukaemia Foundation Australia (LFA), Channel 7, Cancer Australia, Tour de Cure and the Cancer Council SA (CCSA). Professor White has presented more than 170 papers at scientific meetings, and authored more than 100 scientific publications as well as being an inventor on several international patents.
Professor White is the National Flagship Lead for the ALL Stream of Australian Genomics, and SA scientific lead for Zero Children’s Cancer She is an active member of the National Health & Medical Research Council (NHMRC) being a member of the NHMRC Academy, the Translational Research Program Advisory Committee, and the Women in Health Science (WiHS) Committee. She is a member of the Editorial Board for Cancer Letters.
In 2014 she was recognised as the Australian Society for Medical Research (ASMR) Leading Light for her Medical Research and in 2016 was awarded the University of Adelaide James McWha medal. In 2019 she was awarded a prestigious NHMRC Research Excellence Award and awarded the Beat Cancer Women in Leadership Award in 2020.
-
Systems genetics to determine risk of developing diabetes complications
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
-
Stem cell therapies for enteric neuropathies
Dr Stamp is a Group Leader in the Department of Anatomy and Physiology at the University of Melbourne, Australia. Dr Stamp’s PhD research (with Prof Martin Pera, Monash University) focused on the derivation of hepatopancreatic progenitors from human embryonic stem cells. He then joined the lab of Dr Don Newgreen at the Murdoch Childrens Research Institute where he began working on development of the enteric nervous system (ENS), before joining Prof Heather Young’s lab at the University of Melbourne, where he focused on developing a stem cell therapy to treat gut motility disorders such as the paediatric enteric neuropathy Hirschprung disease.
